Canada Life
CRNX

Canada Life’s Crinetics Pharmaceuticals CRNX Stock Holding History

Canada Life’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$395K Hold
10,596
– – ﹤0.01% 1529
2026
Q1 		$387K Buy
10,596
+2,382
+29% +$106K ﹤0.01% 1531
2025
Q4 		$382K Sell
8,214
-14,347
-64% -$639K ﹤0.01% 1552
2025
Q3 		$981K Buy
22,561
+3,342
+17% +$107K ﹤0.01% 1449
2025
Q2 		$554K Hold
19,219
– – ﹤0.01% 1578
2025
Q1 		$646K Hold
19,219
– – ﹤0.01% 1554
2024
Q4 		$981K Buy
19,219
+1,880
+11% +$105K ﹤0.01% 1470
2024
Q3 		$887K Hold
17,339
– – ﹤0.01% 1543
2024
Q2 		$776K Buy
17,339
+12,597
+266% +$582K ﹤0.01% 1568
2024
Q1 		$222K Hold
4,742
– – ﹤0.01% 1815
2023
Q4 		$168K Hold
4,742
– – ﹤0.01% 1862
2023
Q3 		$141K Buy
4,742
+3,285
+225% +$67.7K ﹤0.01% 1907
2023
Q2 		$26K Hold
1,457
– – ﹤0.01% 2095
2023
Q1 		$23K Hold
1,457
– – ﹤0.01% 2181
2022
Q4 		$27K Hold
1,457
– – ﹤0.01% 2201
2022
Q3 		$29K Hold
1,457
– – ﹤0.01% 2189
2022
Q2 		$27K Hold
1,457
– – ﹤0.01% 2201
2022
Q1 		$34K Hold
1,457
– – ﹤0.01% 2247
2021
Q4 		$41K Hold
1,457
– – ﹤0.01% 2219
2021
Q3 		$31K Hold
1,457
– – ﹤0.01% 2350
2021
Q2 		$27K Buy
+1,457
New +$25.6K ﹤0.01% 2424
2021
Q1 		– Sell
-2,292
Closed -$32K – 2596
2020
Q4 		$32K Hold
2,292
– – ﹤0.01% 2428
2020
Q3 		$36K Hold
2,292
– – ﹤0.01% 2260
2020
Q2 		$40K Buy
2,292
+1,837
+404% +$31.3K ﹤0.01% 2292
2020
Q1 		$6K Hold
455
– – ﹤0.01% 2554
2019
Q4 		$11K Buy
+455
New +$8.66K ﹤0.01% 2573
2019
Q3 		– Sell
-858
Closed -$21K – 1382
2019
Q2 		$21K Buy
+858
New +$21.2K ﹤0.01% 2580

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Canada Life's CRNX Position: Q2 2026 in Review

Canada Life held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 10,596 shares worth $395K. The position accounts for ﹤0.01% of the portfolio, ranked #1529.

Canada Life first reported a position in CRNX in Q2 2019 and has held it in 27 quarters since. The position peaked at $981K in Q3 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Canada Life held 10,596 shares of Crinetics Pharmaceuticals worth $395K as of Q2 2026.
  • Canada Life left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Canada Life's portfolio in Q2 2026, its #1529 holding.
  • Canada Life first reported a position in Crinetics Pharmaceuticals in Q2 2019 and has held it in 27 quarters since.
  • Canada Life's Crinetics Pharmaceuticals position peaked at $981K in Q3 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Canada Life's 13F filing for Q2 2026, filed 13 Aug 2026.